secretagogue is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2025-09-16. Where a claim depends on a specific study, the study is described rather than over-claimed.
The molecule contains five residues, including alpha-aminoisobutyric acid, D-2-naphthylalanine, and D-phenylalanine, and it ends in a lysine amide. Non-natural and D-configured residues make the chain less susceptible to common peptidases, which helps explain its resistance to rapid breakdown. Its molecular formula is C38H49N9O5, corresponding to a free-base mass near 711.9 daltons. The C-terminal amide removes a negative charge and is a recurring feature in receptor-active peptides of this family. These structural choices are usually discussed as the basis for its selectivity profile.
Published animal and early human work describes growth hormone release that is separated from comparable rises in adrenocorticotropic hormone and cortisol. Prolactin changes are reported as small in the same studies. Selectivity is attributed to binding at the ghrelin receptor and to the downstream signaling that follows, rather than to differences in how quickly the peptide is cleared. Authors commonly label the compound selective rather than potent, because the same mass produces a smaller growth hormone response than some older secretagogues tested in parallel. Whether that profile holds across species and routes of administration remains an open question.
Human data remain limited and come mainly from small, short-term studies conducted decades ago. The peptide has not received approval as a medicine from major regulators, so current availability is largely as a research chemical. Reported effects on growth hormone pulsatility, appetite, and body composition should be read as preliminary, since few independent groups have replicated the original findings. Analytical characterization of research-grade material varies between suppliers, which complicates comparison across studies. Regulatory status also differs by country, and some jurisdictions classify it as a prescription-only or otherwise restricted item.
Compared with other secretagogues such as GHRP-2, GHRP-6, and hexarelin, ipamorelin is described as more selective. Published animal work reports little or no increase in adrenocorticotropic hormone, cortisol, or prolactin at doses that release growth hormone. This selectivity is the property most often cited in the research literature. Whether the same profile holds across species and dosing schedules remains an open question, since human data are limited and come largely from small studies.
Ipamorelin is a synthetic pentapeptide that belongs to the growth hormone secretagogue family. Its sequence is Aib-His-D-2-Nal-D-Phe-Lys-NH2, and its molecular mass is approximately 711.9 daltons. The compound was described in the late 1990s by researchers seeking molecules that release growth hormone with fewer side effects than earlier secretagogues. It is a laboratory and research compound, not an approved medicine in most jurisdictions.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C38H49N9O5 | Value for the free base |
| Molar mass | 711.9 g/mol | Calculated from the formula |
| Appearance | White to off-white powder | Typical lyophilized form |
| Mechanism class | Ghrelin receptor agonist | Also described as a secretagogue |
| Half-life | About 2 hours | Reported for human circulation |
Long-term storage of the dry powder is typically at minus twenty degrees Celsius or lower, protected from light and moisture. Solutions are commonly kept frozen and thawed only once, because repeated freeze-thaw cycles can promote aggregation and loss of measurable peptide content. Buffers near neutral pH are preferred over strongly acidic or strongly basic conditions. Shipping at ambient temperature is acceptable for short periods when the powder remains sealed and desiccated.
Identity and purity are assessed by complementary methods rather than a single test. Reversed-phase high-performance liquid chromatography separates the peptide from related impurities and reports a percentage purity. Mass spectrometry, most often with electrospray ionization, confirms the expected molecular mass and detects sequence-related variants. Amino acid analysis can verify composition, while water content and residual counterion measurements support the mass balance of a batch. Stability studies under accelerated conditions are used to estimate shelf life, though such estimates carry uncertainty for long-term storage.
Material supplied for research use is normally a white to off-white lyophilized powder. The solid is hygroscopic and is handled in a low-humidity environment to limit water uptake. Bulk quantities are frequently shipped in sealed vials under inert gas. Once reconstituted in water or a neutral buffer, the solution is less stable than the dry powder and is usually divided into single-use aliquots.
Ipamorelin is a synthetic pentapeptide that acts on the growth hormone secretagogue receptor, also known as the ghrelin receptor. Its sequence contains five amino acid residues, including a non-natural residue that increases stability against enzymatic breakdown. The compound was developed in the 1990s as part of research into small peptides that stimulate pituitary hormone release. Unlike larger protein hormones, it can be produced by solid-phase peptide synthesis and characterized by standard analytical methods.
At the receptor level, ipamorelin binds GHS-R1a and triggers signaling through Gq-coupled pathways. Activation leads to calcium release and downstream effects in pituitary somatotroph cells. These events promote the release of growth hormone into circulation. The response depends on the presence of the receptor and on the physiological state of the animal or tissue studied. Because the receptor is also found in other tissues, effects beyond the pituitary have been examined in laboratory models, though the extent of those effects remains an area of ongoing study.
=== South Africa === During the war, the British army included substantial contingents from South Africa itself. There were large communities of English-speaking immigrants and settlers in Natal and Cape Colony, which formed volunteer units that took the field, or local "town guards". At one stage of the war, a "Colonial Division", consisting of five light horse and infantry units under Brigadier General Edward Brabant, took part in the invasion of the Orange Free State. Part of it withstood a siege by Christiaan de Wet at Wepener on the borders of Basutoland. Another large source of volunteers was the uitlander community, many of whom hastily left Johannesburg in the days immediately preceding the war.
== Frequency and depth == The depth of penetration depends on the frequency of the microwaves and the tissue type. The Active Denial System ("pain ray") is a less-lethal directed energy weapon that employs a microwave beam at 95 GHz; a two-second burst of the 95 GHz focused beam heats the skin to a temperature of 130 °F (54 °C) at a depth of 1/64th of an inch (0.4 mm) and is claimed to cause skin pain without lasting damage. Conversely, lower frequencies penetrate deeper; at 5.8 GHz (3.2 mm) the depth most of the energy is dissipated in the first millimeter of the skin; the 2.45 GHz frequency microwaves commonly used in microwave ovens can deliver energy deeper into the tissue; the generally accepted value is 17 mm for muscle tissue. As lower frequencies penetrate deeper into the tissue, and as there are fewer nerve endings in deeper-located parts of the body, the effects of the radio frequency waves (and the damage caused) may not be immediately noticeable. The lower frequencies at high power densities present a significant risk. The microwave absorption is directed by the dielectric constant of the tissue. At 2.5 GHz, this ranges from about 5 for adipose tissue to about 56 for cardiac muscle. As the speed of electromagnetic waves is proportional to the reciprocal of the square root of the dielectric constant, the resulting wavelength in the tissue can drop to a fraction of the wavelength in air; e.g. at 10 GHz the wavelength can drop from 3 cm to about 3.4 mm.
=== Luminous flux: watt equivalent === With the phaseout of the incandescent lamp in the United States and European Union in the early 21st century, manufacturers and sellers of more energy-efficient lamps have compared the visible light output of their lamps to commonly used incandescent lamp sizes with the watt equivalent or watt incandescent replacement (usually with a lowercase w as a unit symbol, as opposed to capital W for the actual wattage). 1 watt incandescent replacement corresponds to 15 lumens. Thus, a 72-watt halogen lamp, a 23-watt compact fluorescent lamp and a 14-watt light-emitting diode lamp, all of which emit 1500 lumens of visible light, are all marketed as "100 watt incandescent replacement" (100w).
On November 21, 2006, EPA ordered DuPont to offer alternative drinking water or treatment for public or private water users living near DuPont's Washington Works plant in West Virginia (and in Ohio), if the level of PFOA detected in drinking water is equal to or greater than 0.5 parts per billion. This measure sharply lowered the previous action level of 150 parts per billion that was established in March 2002. According to a May 23, 2007, Environmental Science & Technology Online article, U.S. Food and Drug Administration research regarding food contact papers as a potential source of PFOA to humans is ongoing. In November 2007, the Centers for Disease Control and Prevention (CDC) published data on PFOA concentrations comparing 1999–2000 vs. 2003–2004 NHANES samples. In October 2021 the EPA proposed to designate PFOA and PFOS as hazardous substances in its PFAS Strategic Roadmap. In September 2022 the EPA proposed to designate as hazardous substances under the Superfund Comprehensive Environmental Response, Compensation, and Liability Act of 1980 (CERCLA). In 2024 EPA published drinking water regulations for PFOA and five other PFAS.
=== Chesapeake Bay restoration === Moore said he would support Chesapeake Bay restoration efforts by promoting "accountability and enforcement" in Maryland, as well as in neighboring states, use federal funds to upgrade water and wastewater systems, and by increasing the number of environmental inspectors. In October 2022, he told Lancaster Farming that he would develop a plan to accelerate projects to improve water quality and cut carbon emissions in his administration's first 100 days, and supported the restoration of the state's Chesapeake Bay Restoration Fund. In July 2023, Moore signed executive orders to refocus cleanup efforts onto shallow areas of the bay and to establish the Council on the Chesapeake and Coastal Bays to research state policy on oyster restoration and harvesting. From October 2023 to December 2025, Moore served as the chair of the Chesapeake Executive Council. During the 2025 legislative session, Moore introduced the Bay Legacy Act, which would promote regenerative farming practices on public lands, increase support for agricultural and oyster farmers, and improve the Maryland Department of Natural Resources's water quality monitoring methods. The Bay Legacy Act passed and was signed into law by Moore in May 2025. In December 2025, Moore, Delaware Governor Matt Meyer, Virginia Governor Glenn Youngkin, and Pennsylvania Governor Josh Shapiro approved a new cleanup plan that extended the Chesapeake Bay restoration effort to 2040 and includes commitments to reducing sediment pollution to the Bay.
Sources: en.wikipedia.org
In 1958, the "University of Pittsburgh Health Center" comprised (1) Schools of Medicine, Dentistry, Pharmacy, Nursing, and the Graduate School of Public Health; (2) Presbyterian, Woman's, Children's, Eye and Ear, and Magee Hospitals; and (3) Falk Clinic, Western Psychiatric Institute and Clinic, Child Guidance Center, Salk Hall, and Central Blood Bank. Through the years, the university and the hospitals moved into an ever-closer alliance. In 1965, the university, Western Psychiatric Institute and Clinic which was managed by the School of Medicine, Presbyterian-University, Magee and Women's, Eye and Ear, and Children's Hospitals incorporated the University Health Center of Pittsburgh (UHCP). In 1969, Montefiore Hospital joined UHCP. In the 1970s, a new model of administration, in which clinical revenues were invested into research, was implemented at Western Psychiatric under the leadership of Thomas Detre. After becoming one of the largest recipients of National Institute of Health funding, Detre assumed leadership of all six university schools of health sciences in the early 1980s. Implementing the same administrative model in those units, the schools of health sciences and the medical center were ultimately transformed into one of the largest centers for biomedical research in the nation.
p-Methoxyphenyl ether (PMP) – Removed by oxidation. Tert-butyl ethers (tBu) – Removed with anhydrous trifluoroacetic acid, hydrogen bromide in acetic acid, or 4 N hydrochloric acid Allyl — Removed with potassium tert‑butoxide DABCO in methanol, palladium on activated carbon, or diverse platinum complexes – conjoined with acid workup. Methyl ethers – Cleavage is by TMSI in dichloromethane or acetonitrile or chloroform. An alternative method to cleave methyl ethers is BBr3 in DCM. See Demethylation § In organic chemistry Tetrahydrofuran (THF) – Removed by acid.
=== Degradation === Glycine is degraded via three pathways. The predominant pathway in animals and plants is the reverse of the glycine synthase pathway mentioned above. In this context, the enzyme system involved is usually called the glycine cleavage system:
People who have ancestry from Sub-Saharan Africa, Asia, or Latin America are more likely to develop a keloid. Among ethnic Chinese in Asia, the keloid is the most common skin condition. In the United States, keloids are more common in African Americans and Hispanic Americans than European Americans. Those who have a family history of keloids are also susceptible since about 1/3 of people who get keloids have a first-degree blood relative (mother, father, sister, brother, or child) who also gets keloids. This family trait is most common in people of African and/or Asian descent. The development of keloids among twins also lends credibility to the existence of a genetic susceptibility to develop keloids. Marneros et al. (1) reported four sets of identical twins with keloids; Ramakrishnan et al. also described a pair of twins who developed keloids at the same time after vaccination. Case series have reported clinically severe forms of keloids in individuals with positive family history and black African ethnic origin.
Sources: en.wikipedia.org
Ziprasidone is approved by the US Food and Drug Administration (FDA) for the treatment of schizophrenia as well as acute mania and mixed states associated with bipolar disorder. Its intramuscular injection form is approved for acute agitation in schizophrenic patients for whom treatment with just ziprasidone is appropriate. In a 2013 study in a comparison of 15 antipsychotic drugs in effectiveness in treating schizophrenic symptoms, ziprasidone demonstrated mild-standard effectiveness. Ziprasidone was 15% more effective than lurasidone and iloperidone, approximately as effective as chlorpromazine and asenapine, and 9–13% less effective than haloperidol, quetiapine, and aripiprazole. Ziprasidone is effective in the treatment of schizophrenia, though evidence from the CATIE trials suggests it is less effective than olanzapine, and equally as effective compared to quetiapine. There are higher discontinuation rates for lower doses of ziprasidone, which are also less effective than higher doses.
Liu Wenhui travelled to Chongqing to negotiate with Liu Xiang, but Liu Xiang would not hand over the confiscated shipment. This was because Liu Xiang had a policy of not allowing any other Sichuanese warlord to gain aircraft (he himself had already acquired a rudimentary air force consisting of several Potez 25 and Breguet 14 bombers). Western sources also agree that Liu Wenhui tried obtaining aircraft, although according to them the aircraft were either seized in Hankou by the central government or crashed en route to Chengdu. The Chinese sources go further by asserting that in May 1931, Liu Wenhui attempted to bribe Liu Xiang's subordinates, including Fan Shaozhen, to join him, but they reported this matter to Liu Xiang, causing Liu to waste 450,000 yuan. An angered Liu supposedly then cut off Liu Xiang's grain supply, forcing the Chongqing warlord to urgently purchase grain from Hunan to prevent hunger. Whatever the matter, it is clear that Liu Wenhui's once-cooperative relationship with his nephew, General Liu Xiang, had soured and turned into a rivalry. On 19 October 1932, Liu Xiang's general, Tang Shizun, and ninety-four other Sichuanese warlords issued a circular telegram to denounce Liu Wenhui. The telegram asserted that Liu was power-hungry, unscrupulous, corrupt, and nepotistic, with no real plans for governing Sichuan and resorting to underhanded tactics such as bribery, backstabbing, and banditry to gain and maintain power. On the eve of war in 1932, Liu Wenhui's armies were estimated at around 120,000 men, slightly outnumbering Liu Xiang's 100,000.
=== Subjects === Participants in phase I drug trials do not gain any direct health benefit from taking part. They are generally paid a fee for their time, with payments regulated and not related to any risk involved. Motivations of healthy volunteers is not limited to financial reward and may include other motivations such as contributing to science and others. In later phase trials, subjects may not be paid to ensure their motivation for participating with potential for a health benefit or contributing to medical knowledge. Small payments may be made for study-related expenses such as travel or as compensation for their time in providing follow-up information about their health after the trial treatment ends.
Sources: en.wikipedia.org
It has not been approved as a therapeutic by major regulators, and the human trial record is small and dated. Material available today is mostly sold as a research chemical for laboratory use. Approval and restriction status varies by country.
It binds the ghrelin receptor, known as the growth hormone secretagogue receptor type 1a. Activation of that receptor triggers signaling that leads to growth hormone release. Selectivity for growth hormone over cortisol and prolactin is the property most often cited for this compound.
Published estimates place the circulating half-life at roughly two hours in humans. Clearance involves peptidase activity and renal handling. Because the peptide is short-lived, release patterns after administration are usually described as pulsatile rather than sustained.
Ipamorelin is a synthetic pentapeptide that stimulates growth hormone release by activating the ghrelin receptor. It is handled as a research tool rather than as a licensed therapeutic product. Its short chain length makes it comparatively simple to synthesize and analyze.